SpringWorks Therapeutics IncNASDAQ:SWTX
- LAST PRICE35.7100
- TODAY'S CHANGE (%)-2.0100 (-5.3287%)
- Bid / Lots35.6900/ 2
- Ask / Lots35.8000/ 4
- Open / Previous Close38.1200 / 37.7200
- Day Range
- 52 Week Range
- Volume345,416
Search Criteria
Filter search criteria using below inputs
Click on magnifying glass icon to search
| Company | Country | Symbol |
|---|
- TSX Comp
- TSX Venture
- DJIA
- S&P 500
- NASDAQ
| Time | Volume | SWTX |
|---|---|---|
| 09:32 ET | 2906 | 38.57 |
| 09:34 ET | 1896 | 37.855 |
| 09:36 ET | 800 | 38.2275 |
| 09:38 ET | 3000 | 37.98 |
| 09:39 ET | 4699 | 37.57 |
| 09:43 ET | 305 | 37.32 |
| 09:45 ET | 600 | 37.41 |
| 09:48 ET | 2607 | 37.88 |
| 09:50 ET | 2020 | 37.665 |
| 09:52 ET | 6781 | 37.6 |
| 09:54 ET | 4900 | 37.57 |
| 09:56 ET | 3500 | 37.485 |
| 09:57 ET | 800 | 37.13 |
| 09:59 ET | 200 | 37.19 |
| 10:01 ET | 300 | 37.33 |
| 10:03 ET | 800 | 37.2 |
| 10:06 ET | 1100 | 37.06 |
| 10:08 ET | 4234 | 36.81 |
| 10:10 ET | 100 | 36.685 |
| 10:12 ET | 900 | 36.65 |
| 10:14 ET | 500 | 36.58 |
| 10:15 ET | 700 | 36.635 |
| 10:17 ET | 5530 | 36.71 |
| 10:19 ET | 100 | 36.71 |
| 10:21 ET | 350 | 36.4316 |
| 10:24 ET | 600 | 36.4 |
| 10:26 ET | 400 | 36.31 |
| 10:28 ET | 4308 | 36.41 |
| 10:30 ET | 2402 | 36.26 |
| 10:33 ET | 2191 | 36.203 |
| 10:35 ET | 2800 | 36.155 |
| 10:37 ET | 1960 | 36.2 |
| 10:39 ET | 2600 | 36.28 |
| 10:42 ET | 2915 | 36.3 |
| 10:44 ET | 600 | 36.29 |
| 10:46 ET | 950 | 36.24 |
| 10:48 ET | 300 | 36.15 |
| 10:50 ET | 300 | 36.19 |
| 10:51 ET | 200 | 36.11 |
| 10:53 ET | 500 | 36.16 |
| 10:55 ET | 100 | 36.18 |
| 10:57 ET | 807 | 36.185 |
| 11:00 ET | 3900 | 36.27 |
| 11:02 ET | 6907 | 36.44 |
| 11:04 ET | 6051 | 36.49 |
| 11:06 ET | 400 | 36.45 |
| 11:08 ET | 1100 | 36.43 |
| 11:09 ET | 11089 | 36.44 |
| 11:11 ET | 6500 | 36.47 |
| 11:13 ET | 3520 | 36.4599 |
| 11:15 ET | 1500 | 36.57 |
| 11:18 ET | 2382 | 36.49 |
| 11:20 ET | 1300 | 36.5 |
| 11:22 ET | 3218 | 36.475 |
| 11:24 ET | 1400 | 36.48 |
| 11:26 ET | 1800 | 36.485 |
| 11:27 ET | 900 | 36.49 |
| 11:29 ET | 20934 | 36.52 |
| 11:31 ET | 21846 | 36.42 |
| 11:33 ET | 12797 | 36.53 |
| 11:36 ET | 5583 | 36.51 |
| 11:38 ET | 1100 | 36.515 |
| 11:40 ET | 1000 | 36.48 |
| 11:42 ET | 4296 | 36.26 |
| 11:44 ET | 100 | 36.28 |
| 11:45 ET | 1400 | 36.21 |
| 11:47 ET | 4960 | 36.04 |
| 11:49 ET | 1000 | 36.02 |
| 11:51 ET | 2700 | 35.97 |
| 11:54 ET | 3529 | 35.97 |
| 11:56 ET | 4572 | 35.99 |
| 11:58 ET | 700 | 35.89 |
| 12:00 ET | 200 | 35.9 |
| 12:02 ET | 700 | 35.81 |
| 12:03 ET | 500 | 35.88 |
| 12:05 ET | 2218 | 35.7 |
| 12:09 ET | 2639 | 35.62 |
| 12:12 ET | 976 | 35.58 |
| 12:14 ET | 8620 | 35.53 |
| 12:16 ET | 300 | 35.535 |
| 12:18 ET | 4596 | 35.6 |
| 12:20 ET | 3736 | 35.68 |
| 12:21 ET | 1560 | 35.63 |
| 12:23 ET | 2012 | 35.625 |
| 12:25 ET | 1684 | 35.49 |
| 12:27 ET | 3591 | 35.57 |
| 12:30 ET | 600 | 35.59 |
| 12:32 ET | 1747 | 35.535 |
| 12:34 ET | 600 | 35.52 |
| 12:36 ET | 3170 | 35.8 |
| 12:38 ET | 1135 | 35.84 |
| 12:39 ET | 500 | 35.8 |
| 12:41 ET | 500 | 35.8 |
| 12:43 ET | 3130 | 35.765 |
| 12:45 ET | 1100 | 35.71 |
Jul 2, 2024
Kuehn Law Encourages Investors of SpringWorks, Therapeutics Inc. to Contact Law Firm, from 12:49PM ET on Tuesday Jul 02, 2024 by Dow Jones
12:49PM ET on Tuesday Jul 02, 2024 by Dow Jones
Jul 1, 2024
| Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
|---|---|---|---|
SpringWorks Therapeutics Inc | 2.9B | -6.9x | --- |
Apogee Therapeutics Inc | 2.9B | -23.5x | --- |
Geron Corp | 2.8B | -13.4x | --- |
Morphic Holding Inc | 2.8B | -16.2x | --- |
MoonLake Immunotherapeutics | 3.0B | -59.6x | --- |
Vitaspring Biomedical Co. Ltd | 3.1B | 3,311.3x | --- |
Company Information
SpringWorks Therapeutics, Inc. is a commercial-stage biopharmaceutical company focused on severe rare diseases and cancer. OGSIVEO (nirogacestat) is the Company's Food and Drug Administration (FDA)-approved therapy. OGSIVEO (nirogacestat) is approved in the United States for the treatment of adult patients with progressing desmoid tumors who require systemic treatment. The Company also has a diversified targeted therapy pipeline spanning solid tumors and hematological cancers, with programs ranging from preclinical development through advanced clinical trials. Its ongoing developments include Nirogacestat for treatment of ovarian granulosa cell tumors, Nirogacestat in combination with B-cell maturation antigen (BCMA)-targeted agents, Mirdametinib Phase 2b ReNeu trial in NF1-PN and Brimarafenib (BGB-3245). The Company's early-stage pipeline includes SW-682, an investigational oral, small molecule TEA Domain (TEAD), inhibitor that is evaluated in Hippo-mutant solid tumors.
Contact Information
- Headquarters
- 100 Washington BlvdSTAMFORD, CT, United States 06902-9302
- Phone
- 203-883-9490
- Fax
- 302-655-5049
Executives
- Independent Chairman of the Board
- Daniel Lynch
- Chief Executive Officer, Director
- Saqib Islam
- Chief Financial Officer
- Francis Perier
- Chief Operating Officer
- Badreddin Edris
- Chief People Officer
- Daniel Pichl
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $2.9B |
|---|---|
Revenue (TTM) | $26.5M |
Shares Outstanding | 74.1M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | 0.78 |
EPS | $-5.15 |
Book Value | $8.52 |
P/E Ratio | -6.9x |
Price/Sales (TTM) | 108.9 |
Price/Cash Flow (TTM) | --- |
Operating Margin | -1,358.05% |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.
